Biomarkers in epilepsy and OV329 program updates June 12, 2025 © Copyright 2025 Ovid Therapeutics Welcome Dr. Jeremy Levin Chairman & Chief Executive Officer © Copyright 2025 Ovid Therapeutics © Copyright 2025 Ovid Therapeutics 2 Forward-looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, the potential therapeutic benefits of Ovid's current or future product candidates and pipelin ...

Ovid Therapeutics (OVID) Update / Briefing June 12, 2025 09:30 AM ET Speaker0 Thank you very much for coming. Those of you here, wonderful to see you and those many of you online, I really appreciate you taking the time to spend with us today and hopefully you'll visit with us one on one. Today we're going to talk about biomarkers in epilepsy and our three twenty nine program. I'd like to really encourage you to dig in. This is an important moment for not just for Ovid, actually for the industry. Our pipeli ...

Interested in attending or participating remotely: NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr ...